Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing
Sarah V. Gerhart(GlaxoSmithKline (United States)), Olena Barbash(GlaxoSmithKline (United States))
Cited by 205